[1]张霞)),千新来)#,崔静),等.乳腺良、恶性病变组织中Livin和Smac的表达*[J].郑州大学学报(医学版),2009,(04):735-738.
 ZHANG Xia),QIAN Xinlai),CUI Jing),et al.Expressions of Livin and Smac in benign and malignant breast lesions[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):735-738.
点击复制

乳腺良、恶性病变组织中Livin和Smac的表达* ()
分享到:

《郑州大学学报(医学版)》[ISSN:1671-6825/CN:41-1340/R]

卷:
期数:
2009年04期
页码:
735-738
栏目:
应用研究
出版日期:
2009-07-01

文章信息/Info

Title:
Expressions of Livin and Smac in benign and malignant breast lesions
作者:
张霞1)2)千新来1)#崔静1)李新强1)李永真1)张洁1)赵杰1)治亚平1)
1)新乡医学院病理学教研室 新乡 4530032)郑州大学出版社 郑州 450052
Author(s):
ZHANG Xia12)QIAN Xinlai1)CUI Jing1)ZHANG Jie1)ZHAO Jie1)YE Yaping1)
1)Department of Pathology, Xinxiang Medical University, Xinxiang 4530032)Zhengzhou Univercity Press,Zhengzhou 450052
关键词:
乳腺肿瘤LivinSmac
Keywords:
breast carcinomaSmac Livin
分类号:
R737.9
摘要:
观察乳腺良、恶性病变组织中Smac 和凋亡蛋白抑制因子家族成员Livin的表达情况。方法:选取乳腺良性增生及乳腺导管癌组织共152例(乳腺良性增生41例,乳腺导管内癌20例,乳腺浸润性导管癌91例;有淋巴结转移61例,无淋巴结转移30例),对照癌组织HE切片,选择富有肿瘤细胞且无出血坏死的区域,手工制备82点阵和70点阵的组织芯片2片。另取18例手术远端正常乳腺组织常规切片作对照。采用免疫组织化学SP法检测上述组织中Livin和Smac蛋白的表达情况。结果:①正常乳腺、乳腺良性增生、乳腺导管内癌和乳腺浸润性导管癌组织中Livin蛋白阳性率分别为11.1%(2/18)、43.9%(18/41)、80.0%(16/20)和90.1%(82/91),差异具有统计学意义(χ2=60.800,P<0.05)。Livin蛋白阳性率与乳腺浸润性导管癌患者的年龄、肿瘤大小、淋巴结转移、TNM分期、ER、PR无关(P均>0.05)。②正常乳腺、乳腺良性增生、乳腺导管内癌和乳腺浸润性导管癌组织中Smac蛋白阳性率分别为83.3%(15/18)、78.0%(32/41)、90.0%(18/20)和50.5%(46/91),差异有统计学意义(χ2=19.646,P<0.05)。Smac蛋白阳性率与乳腺浸润性导管癌患者的年龄、肿瘤大小、ER、PR无关(P均>0.05),与淋巴结转移有关(χ2=32.772,P<0.05)。结论:Livin及Smac蛋白的异常可能在乳腺癌的发生与演进中起重要作用。
Abstract:
To investigate the expressions of Livin and Smac in breast benign and malignant lesions.Methods:A total of 152 samples including 18 cases of invasive breast distal normal breast tissue, 41 cases of benign breast hyperplasia, 20 cases of intraductal breast cancer, 91 cases with breast ductal carcinoma (61 cases with lymph node metastasis,30 cases without lymph node metastasis) were collected to detect Livin and Smac proteins using immunohistochemical method and tissue microarrays analysis.Results: ①The positive rates of Livin protein in normal tissue, benign breast hyperplasia, intradactal breast cancer and breast ductal carcinoma tissue were 11.1%(2/18), 43.9%(18/41), 80.0%(16/20),and 90.1%(82/91),respeetively increased by turn(χ2=60.800,P<0.05).The positive rates of Smac protein in tissues mentioned above were 83.3%(15/18), 78.0%(32/41),90.0%(18/20),and 50.5%(46/91),respectively.There were significantly differences in the positive rate of Smac in the 4 groups(χ2=19.646,P<0.05). Smac expression was not correlated with patient’s age, the size of the tumor, ER, and PR (P>0.05),but correlated with lymph node metastasis(χ2=32.772,P<0.05).Conclusion:Livin and Smac might play an important role in the carcinogenesis and progression in breast carcinoma.

参考文献/References:

[1]Yang QH, Du C. Smac/DIABLO selectively reduces the levels of cIAP1 and cIAP2 but not that of XIAP and livin in HeLa cells[J]. J Biol Chem, 2004, 279(17):16 963
[2]Kasof GM, Gomes BC. Livin, a novel inhibitor of apoptosis protein family member[J]. J Biol Chem, 2001, 276(5):3 238
[3]Vucic D, Stennicke HR, Pisabarro MT, et al. MLIAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas[J]. Curr Biol, 2000, 10(21):1 359
[4]Li JH, He WJ, He YJ. Expression and clinical significance of Survivin and Livin in DukesoB colorectal cancer[J]. Ai Zheng, 2007, 26(5):547
[5]Song T, Hong BF, Gao JP, et al. Expression of apoptosis inhibitor gene Livin in bladder transitional cell carcinoma and clinical implication thereof[J]. Zhonghua Yi Xue Za Zhi, 2007, 87(12):806
[6]Yuan D, Liu L, Gu D. Transcriptional regulation of livin by betacatenin/TCF signaling in human lung cancer cell lines[J].Mol Cell Biochem, 2007, 306(1/2):171
[7]CrnkovicMertens I, Muley T, Meister M, et al. The antiapoptotic livin gene is an important determinant for the apoptotic resistance of nonsmall cell lung cancer cells[J]. Lung Cancer, 2006, 54(2):135
[8]孙廷谊,张云汉,孔令非.组织芯片的研制及效果[J].郑州大学学报:医学版,2007,42(1):116
[9]鲁祥石,刘彦龙,王涤,等.凋亡抑制蛋白Livin和Survivin在乳腺癌中的表达及意义[J]. 中国癌症杂志, 2007, 17(7):542
[10]赵进明,朱志华,吴秋良,等. Smac在Ⅰ~Ⅱ期非小细胞肺癌组织中的表达及其临床意义[J]. 癌症, 2006, 25(5):631

相似文献/References:

[1]曾宪旭△,王玉萍,楚天骄,等.乳腺导管浸润癌组织中促肝细胞再生磷酸酶蛋白的表达*[J].郑州大学学报(医学版),2010,(01):57.
 ZENG Xianxu,WANG Yuping,CHU Tianjiao,et al.Expression of phosphatase of regenerating liver3 protein in breast invasive ductal carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):57.
[2]赵春临),陈文超),张谢夫)#,等.胃肠道间质瘤组织中Livin、Ki67和MMP9的表达及生存分析[J].郑州大学学报(医学版),2009,(06):1232.
 ZHAO Chunlin),CHEN Wenchao),ZHANG Xiefu),et al.Relationship between expression of Livin, Ki67 and MMP9 in gastrointestinal stromal tumor tissue and its prognosis[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):1232.
[3]王晓娟△,王春芳,边爱平,等.子宫内膜异位症患者子宫内膜组织中Livin和Caspase3蛋白的表达[J].郑州大学学报(医学版),2009,(05):1029.
 WANG Xiaojuan,WANG Chunfang,BIAN Aiping,et al.Expression of Livin and Caspase3 protein in endometrium of patients with endometriosis[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):1029.
[4]袁志浩,乔保平#,李琦.肾癌组织中Livin和Smac蛋白的表达[J].郑州大学学报(医学版),2009,(02):397.
 YUAN Zhihao,QIAO Baoping,LI Qi.Expression of Livin and Smac in renal cell carcinoma tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2009,(04):397.
[5]裴新红,吕鹏威.早期乳癌乳晕内弧形切口保乳手术77例体会[J].郑州大学学报(医学版),2009,(01):208.
[6]杨玲竹△,马丽红.稽留流产绒毛组织中Fas相关死亡结构域蛋白和Livin的表达[J].郑州大学学报(医学版),2010,(04):582.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):582.
[7]杨玲竹△,马丽红.稽留流产绒毛组织中Fas相关死亡结构域蛋白和Livin的表达[J].郑州大学学报(医学版),2010,(04):582.
 [J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2010,(04):582.
[8]高萍△,臧文巧,王涛.食管鳞状细胞癌组织中Livin与半胱氨酸蛋白酶3的表达[J].郑州大学学报(医学版),2010,(06):888.
[9]赵倩△,边爱平,王春芳. 子宫内膜异位症患者内膜组织中Livin和Smac蛋白的表达[J].郑州大学学报(医学版),2011,(02):228.
 ZHAO Qian,BIAN Aiping,WANG Chunfang. Expression of Livin and Smac protein in endometrium of endometriosis patients[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2011,(04):228.
[10]王大伟,王喜梅#,刘林嶓,等.病理性瘢痕组织中Livin和Smac的表达[J].郑州大学学报(医学版),2012,(02):209.
 WANG Dawei,WANG Ximei,LIU Linbo,et al.Expressions of Livin and Smac in pathologic scar tissue[J].JOURNAL OF ZHENGZHOU UNIVERSITY(MEDICAL SCIENCES),2012,(04):209.

备注/Memo

备注/Memo:
*卫生部科研基金资助项目WKJ20072022;河南省高校杰出科研人才创新工程资助基金项目2007KYCX013 #通讯作者,男,1966年,博士,副教授,研究方向:癌变机制及肿瘤生物治疗,Email:qxlfssws@163.com
更新日期/Last Update: 2010-05-18